Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer

Journal article

Miller P. et al, (2023), Cell Death & Differentiation, 30, 1619 - 1635

Regulation of immunological tolerance by the p53-inhibitor iASPP

Journal article

Akama-Garren EH. et al, (2023), Cell Death & Disease, 14

Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis

Journal article

Al Moussawi K. et al, (2022), Cell Reports, 41, 111503 - 111503

Ciliogenesis and Hedgehog signalling are supressed downstream of KRas during acinar-ductal metaplasia

Journal article

Bangs FK. et al, (2020), Disease Models & Mechanisms

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells

Journal article

Freedman JD. et al, (2018), Cancer Research, 78, 6852 - 6865

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

Journal article

Freedman JD. et al, (2017), EMBO Molecular Medicine, 9, 1067 - 1087

ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome

Journal article

Zak J. et al, (2016), Cell Death & Differentiation, 23, 1973 - 1984

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy

Journal article

Lu M. et al, (2014), FEBS Letters, 588, 2616 - 2621